SCHEMBL5607141

SCHEMBL5607141

NC(Cc1ccc(NC(=O)c2cccnc2)cc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.64
NPC1 O15118 3/20 0.64
SMN1; SMN2 Q16637 3/20 0.64
ITGB3 P05106 1/20 0.58
ITGAV P06756 1/20 0.58
ITGA2B P08514 1/20 0.58
ROCK2 O75116 1/20 0.58
ROCK1 Q13464 1/20 0.58
TP53 P04637 2/20 0.57
NPSR1 Q6W5P4 2/20 0.56
ALDH1A1 P00352 2/20 0.56
LMNA P02545 1/20 0.56
HIF1A Q16665 1/20 0.56
KMT2A Q03164 2/20 0.55
MAPT P10636 1/20 0.55
GFER P55789 1/20 0.55
MEN1 O00255 1/20 0.55
NAMPT P43490 2/20 0.54
GAA P10253 1/20 0.54
TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607137 1.00 RAB9A (0.64) RAB9ANPC1SMN1; SMN2ITGB3ITGAV
SCHEMBL21689989 0.88 TRPV1 (0.64) RAB9ANPC1LMNANAMPTGAA
SCHEMBL7356331 0.87 RAB9A (0.64) RAB9ANPC1SMN1; SMN2ROCK2ROCK1
Hydrochloric Acid SCHEMBL7356325 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2ROCK2ROCK1
Hydrochloric Acid SCHEMBL27573780 0.86 RAB9A (0.62) RAB9ANPC1SMN1; SMN2ROCK2ROCK1
SCHEMBL757263 0.85 ITGB3 (0.67) RAB9ANPC1SMN1; SMN2ITGB3ITGAV
SCHEMBL7769029 0.85 ITGB3 (0.67) RAB9ANPC1SMN1; SMN2ITGB3ITGAV
SCHEMBL19234470 0.85 ITGB3 (0.67) RAB9ANPC1SMN1; SMN2ITGB3ITGAV
SCHEMBL5076615 0.85 TSHR (0.64) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL5076607 0.85 TSHR (0.64) RAB9ANPC1SMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP RAB9A 1699/4885NPC1 2647/4885SMN1; SMN2 1582/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.